New anti-complement drugs: Not so far away

Blood

Volumn 123, Issue 13, 2014, Pages 1975-1976

  Thurman, Joshua M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; HEMATOLOGIC AGENT;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; ERYTHROCYTE; HEMOLYSIS; HUMAN; NONHUMAN; NOTE; OPSONIZATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; SOMATIC MUTATION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; PEPTIDES, CYCLIC;

EID: 84897495211     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-555805     Document Type: Note

References (6)

1. Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094-2101.
2. Pangburn MK, Müller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980;152(4):1102-1114. (Pubitemid 10010889)
3. Müller-Eberhard HJ. The membrane attack complex. Springer Semin Immunopathol. 1984;7(2-3):93-141. (Pubitemid 14010633)
4. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256-1264. (Pubitemid 350076509)
5. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840-1847. (Pubitemid 351451491)
6. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained ef ficacy and improved survival. Blood. 2011;117(25):6786-6792.